Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: Pooled analysis of 3 fibromyalgia trials

Journal of Clinical Rheumatology

Volumn 20, Issue 4, 2014, Pages 195-202

  Mease, Philip J ^a,c   Palmer, Robert H ^b   Wang, Yong ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Seattle Rhumatology Associates   (United States)

Author keywords

fatigue; fibromyalgia; milnacipran

Indexed keywords

MILNACIPRAN; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; CYCLOPROPANE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDIMENSIONAL FATIGUE INVENTORY; PAIN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; AGED; DOUBLE BLIND PROCEDURE; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; CYCLOPROPANES; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901751065     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000103     Document Type: Article

References (61)

1. Dupond JL. Fatigue in patients with rheumatic diseases. Joint Bone Spine. 2011;78:156-160.
2. Kirwan JR, Hewlett S. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol. 2007;34:1171-1173. (Pubitemid 46774869)
3. Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34:1174-1177. (Pubitemid 46774870)
4. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36:2318-2329.
5. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
6. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology project. Arthritis Care Res. 2013;65:786-792.
7. Turk DC, Dworkin RH, Revicki D, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137:276-285. (Pubitemid 351853291)
8. Bennett RM, Jones J, Turk DC, et al. An Internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
9. Choy E, Perrot S, Leon T, et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010;10:102.
10. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996;23:1407-1417. (Pubitemid 26258765)
11. Guymer EK, Clauw DJ. Treatment of fatigue in fibromyalgia. Rheum Dis Clin North Am. 2002;28:367-378. (Pubitemid 34733190)
12. Zautra AJ, Fasman R, Parish BP, et al. Daily fatigue in women with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Pain. 2007;128:128-135. (Pubitemid 46216603)
13. Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am. 2009;35:215-232.
14. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114-120.
15. Nicassio PM, Moxham EG, Schuman CE, et al. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain. 2002;100:271-279. (Pubitemid 35449238)
16. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol. 1995;22:639-643.
17. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
19. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728-733.
20. Crawford BK, Piault EC, Lai C, et al. Assessing fibromyalgia-related fatigue: content validity and psychometric performance of the fatigue visual analog scale in adult patients with fibromyalgia. Clin Exp Rheumatol. 2011;29:S34-S43.
21. Ericsson A, Bremell T, Mannerkorpi K. Usefulness of multiple dimensions of fatigue in fibromyalgia. J Rehabil Med. 2013;45:685-693.
22. Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie. 2003;26:140-144. (Pubitemid 36677078)
23. Lin JM, Brimmer DJ, Maloney EM, et al. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr. 2009;7:18.
24. Hinz A, Fleischer M, Brahler E, et al. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry. 2011;33:462-468.
25. Smets EM, Garssen B, Cull A, et al. Application of the Multidimensional Fatigue Inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer. 1996;73:241-245. (Pubitemid 26028340)
26. Fillion L, Gelinas C, Simard S, et al. Validation evidence for the French Canadian adaptation of the Multidimensional Fatigue Inventory as a measure of cancer-related fatigue. Cancer Nurs. 2003;26:143-154. (Pubitemid 36396853)
27. Hagelin CL, Wengstrom Y, Runesdotter S, et al. The psychometric properties of the Swedish Multidimensional Fatigue Inventory MFI-20 in four different populations. Acta Oncol. 2007;46:97-104.
28. Purcell A, Fleming J, Bennett S, et al. Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population. Support Care Cancer. 2010;18:307-315.
29. Tian J, Hong JS. Validation of the Chinese version of Multidimensional Fatigue Inventory-20 in Chinese patients with cancer. Support Care Cancer. 2012;20:2379-2383.
30. Gentile S, Delaroziere JC, Favre F, et al. Validation of the French 'Multidimensional Fatigue Inventory' (MFI 20). Eur J Cancer Care (Engl). 2003;12:58-64. (Pubitemid 37255607)
31. Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjogren's syndrome. Ann Rheum Dis. 1998;57:291-295. (Pubitemid 28351097)
32. Rupp I, Boshuizen HC, Jacobi CE, et al. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum. 2004;51:578-585. (Pubitemid 39056245)
33. Goodchild CE, Treharne GJ, Booth DA, et al. Measuring fatigue among women with Sjogren's syndrome or rheumatoid arthritis: a comparison of the Profile of Fatigue (ProF) and the Multidimensional Fatigue Inventory (MFI). Musculoskeletal Care. 2008;6:31-48.
34. Pouchot J, Kherani RB, Brant R, et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol. 2008;61:705-713.
35. Gunaydin R, Goksel Karatepe A, Cesmeli N, et al. Fatigue in patients with ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep disturbance. Clin Rheumatol. 2009;28:1045-1051.
36. Goligher EC, Pouchot J, Brant R, et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol. 2008;35:635-642. (Pubitemid 351500059)
37. Fishbain DA, Lewis J, Cole B, et al. Multidisciplinary pain facility treatment outcome for pain-associated fatigue. Pain Med. 2005;6:299-304. (Pubitemid 41725954)
38. Le Gal M, Mainguy Y, Le Lay K, et al. Linguistic validation of six patient-reported outcomes instruments into 12 languages for patients with fibromyalgia. Joint Bone Spine. 2010;77:165-170.
39. Ericsson A, Mannerkorpi K. Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil. 2007;29:1665-1670. (Pubitemid 351485786)
40. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409.
41. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988-2004.
42. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:2745-2756.
43. Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010;37:851-859.
44. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172. (Pubitemid 20098653)
45. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio. TX: Psychological Corporation; 1996.
46. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100. (Pubitemid 18045797)
47. Khanna D, Pope JE, Khanna PP, et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol. 2008;35:2339-2343.
48. Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11:R170.
49. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537-545. (Pubitemid 36577256)
50. Pan JC, Bressler DN. Fatigue in rheumatologic diseases. Phys Med Rehabil Clin N Am. 2009;20:373-387.
51. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
52. Arnold LM, Williams DA, Hudson JI, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64:885-894.
53. Norheim KB, Jonsson GOmdal R. Biological mechanisms of chronic fatigue. Rheumatology (Oxford). 2010;50:1009-1018.
54. Davis MP, Walsh D. Mechanisms of fatigue. J Support Oncol. 2010;8:164-174.
55. Clauw DJ. Perspectives on fatigue from the study of chronic fatigue syndrome and related conditions. PM&R. 2010;2:414-430.
56. Silverman MN, Heim CM, Nater UM, et al. Neuroendocrine and immune contributors to fatigue. PM&R. 2010;2:338-346.
57. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry. 2009;22:75-83.
58. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry. 2002;63:7-8. (Pubitemid 34113479)
59. Arnold LM, Wang F, Ahl J, et al. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011;13:R86.
60. Uçeyler N, Sommer C, Walitt B, et al. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:CD010782.
61. Arnold LM, Clauw DJ, Dunegan LJ, et al. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012;87:488-496.